Business Wire

Armis Named Leader in GigaOm Radar Report for Operational Technology (OT) Security

10.7.2023 15:00:00 EEST | Business Wire | Press release

Share

Armis, the leading asset visibility and security company, today announced that it has been named a leader in the GigaOm Radar Report for Operational Technology (OT) Security.

“We’re proud to be recognized by GigaOm as a leader in operational technology security,” said Nadir Izrael, CTO and Co-founder, Armis. “It’s critical to secure the hardware and software systems that control physical devices and the industrial processes that our society depends on. Our mission is to ensure the availability, reliability and safety of these industrial control systems by mitigating cybersecurity risks that could otherwise lead to system failures, operational disruptions or physical damages.”

Within the GigaOm Radar for OT Security, Armis is:

  • positioned in the Leaders ring, recognized for being a highly scalable platform and for the solution's strong vulnerability management features, practical AI and dynamic segmentation.
  • housed in the Innovation/Platform Play quadrant. The Innovation positioning highlights technical innovation while the Platform Play displays a broader platform focus and commitment to a comprehensive feature set.
  • recognized as a Fast Mover when evaluating strategy and pace of innovation in this forward-looking assessment plotting the current projected positioning of each vendor over a 12- to 18-month window.

“Of all the vendors we looked at, Armis provided the fastest time to value and the widest coverage. Because it’s cloud-based, Armis is also simple to manage. All these factors made it easy to choose Armis, frankly,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals. “Thanks to Armis, we’ve already uncovered a series of potential cyber risks. Without the Armis deployment, we never would have known they existed. It has already paid for itself.”

Armis is rated exceptional in the report for its:

  • SaaS solution which serves large enterprises and manufacturers
  • AI technologies for threat detection and rendezvous capabilities which GigaOm considered differentiating and critical in this sector
  • product evaluation metrics, specifically scalability and compliance.

Additionally, Armis was recognized as the only OT vendor with FedRAMP Moderate ATO, ISO 27001, ISO 28018 Best Practices and SOC 2 Type II certifications.

“A key differentiator for Armis is its excellent knowledge base, which contains critical information about the billions of devices under its monitoring umbrella, including both the device profile and the expected behaviors of that device,” said Chris Ray, Research Analyst at GigaOm. “This solution is able to leverage that information to quickly identify unusual or abnormal conditions that legacy security tools (like an intrusion detection system, or IDS) would not be able to detect. Armis has a strong focus on healthcare, manufacturing and the public sector. From our point of view, the product complements existing OT security solutions.”

“From an overall security perspective, visibility into the manufacturing area was a big thing for us,” said Shem Stephens, Security Engineer at Colgate-Palmolive. “We needed a tool to see what our plants are doing in order to better support them in terms of their security posture— and Armis fit the bill perfectly. Our auditing team uses Armis to look into areas of opportunity at our plants. And systems engineers use Armis to see when a programmable logic controller (PLC) was last changed out. They have that information at their fingertips now. As our leadership continues to collaborate with Armis leadership, we can create these unique use cases that provide tremendous benefits for specific teams or individuals.”

To read the full GigaOm Radar Report for Operational Technology (OT) Security, please visit: https://www.armis.com/analyst-reports/gigaom-radar-for-ot-security/

For the Armis blog surrounding this report, go to: https://www.armis.com/blog/armis-named-leader-in-gigaom-radar-report-for-operational-technology-ot-security/

Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/

About Armis

Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye